The clinical significance of insulin resistance in non-diabetic patients with early forms of non-alcoholic fatty liver disease
- Authors: Shipovskaya AA1, Dudanova OP1, Kurbatova IV2
-
Affiliations:
- Petrozavodsk State University, Institute of Medicine, Department of Propaedeutics of Internal Diseases and Hygiene
- The Institute of Biology - a separate subdivision of Karelian Research Centre of Russian Academy of Sciences
- Issue: Vol 90, No 8 (2018)
- Pages: 63-68
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32791
- DOI: https://doi.org/10.26442/terarkh201890863-68
- ID: 32791
Cite item
Full Text
Abstract
Aim. To assess the presence of insulin resistance (IR) in non-diabetic patients with early forms of non-alcoholic fatty liver disease (NAFLD) - liver steatosis (LS) and steatohepatitis (SH) of mild activity and the influence of IR on the clinical course of these diseases. Materials and methods. 134 patients with NAFLD were examined: 54 with LS and 80 with SH. The control group consisted of 37 healthy donors. Anthropometric parameters (body mass index (BMI), waist circumference (WC)), clinical and biochemical blood indices, including the blood level of cytokeratin-18 fragments (CK-18), TNF-α and IL-6 cytokines, insulin were evaluated. The HOMA index and the fibrosis index (NAFLD FS) were calculated. Patients were divided into groups: I - with the absence of IR (HOMA-index <2.7), II - with the presence of IR (HOMA-index> 2.7). Results and discussion. Indicators of hepatic injury, inflammation, cholestasis, fibrosis and atherogenic dyslipidemia are higher in patients with LS of group II (with IR) than in group I patients (without IR). BMI, WC, γ-glutamil transpeptidase, CK-18 and fibrosis index are significantly higher in group II patients with SH compared with group I, there is no significant difference in the level of cytolysis, inflammation and dyslipidemia indices. A high incidence of IR in non-diabetic patients with LS (37.0%) and SH (55.0%) was found and the effect of IR on the clinical course of these diseases was revealed. Conclusion. Insulin resistance in non-diabetic patients with NAFLD was detected in SH (55.0%) with higher frequency than in LS (37.0%). In LS, IR is associated with impaired hepatic cell damage, intrahepatic cholestasis, atherogenic dyslipidemia and fibrosis. In SH, IR is combined with reliable growth in indicators of hepatocyte apoptosis, cytokine proinflammatory status and fibrosis. IR determines the progressing course of NAFLD, promoting the transformation of steatosis into steatohepatitis and steatohepatitis into fibrosis and liver cirrhosis.
Full Text
##article.viewOnOriginalSite##About the authors
A A Shipovskaya
Petrozavodsk State University, Institute of Medicine, Department of Propaedeutics of Internal Diseases and Hygieneаспирант каф. пропедевтики внутренних болезней и гигиены Медицинского института ПетрГУ Petrozavodsk, Russia
O P Dudanova
Petrozavodsk State University, Institute of Medicine, Department of Propaedeutics of Internal Diseases and Hygiene
Email: odudanova@gmail.com
д.м.н., проф., зав. каф. пропедевтики внутренних болезней и гигиены Медицинского института ПетрГУ Petrozavodsk, Russia
I V Kurbatova
The Institute of Biology - a separate subdivision of Karelian Research Centre of Russian Academy of Sciencesк.б.н., н.с. лаб. генетики ИБ КарНЦ РАН Petrozavodsk, Russia
References
- Ивашкин В.Т., Драпкина О.М., Маев И.В., Трухманов А.С., Блинов Д.В., Пальгова Л.К., Цуканов В.В., Ушакова Т.И. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно - поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;(6):31-41.
- Benedict M, Zhang X. Non - alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9(16):715-732. doi: 10.4254/wjh. v9.i16.715
- Byrne C.D, Targher G. Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease: Implications for Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2014;34(6):1155-1161. doi: 10.1161/atvbaha.114.303034
- Boutens L, Stienstra R. Adipose tissue macrophages: going off track during obesity. Diabetologia. 2016;59:879-884. doi: 10.1007/s00125-016-3904-9
- Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi L. Nonalcoholic fatty liver disease: Evolving paradigms. E World J Gastroenterol. 2017;23(36):6571-6592. doi: 10.3748/wjg. v23. i36.6571
- Petta S, Gastaldelli A, Rebelos E, Bugianesi E, Messa P, Miele L, Svegliati-Baroni G, Valenti L, Bonino F. Pathophysiology of Non Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17(12):pii: E2082.
- Pasarín M, Abraldes J.G, Liguori E, Kok B, La Mura V. Intrahepatic vascular changes in non - alcoholic fatty liver disease: potential role of insulin - resistance and endothelial dysfunction. World J Gastroenterol. 2017;23(37):6777-6787. doi: 10.3748/wjg.v23.i37.6777
- Ройтберг Г.Е., Шархун О.О. Особенности прогрессирования поражения печени при инсулинорезистентности. Медицина. 2017;5:99-107.
- Jung K.Y, Cho S.Y, Kim H.J, Kim S.B, Song I.H. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology. J Clin Gastroenterol. 2014;48(10):883-888. doi: 10.1097/mcg.0000000000000065
- Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non - alcoholic steatohepatitis and its individual histological features: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46:1074-1087. doi: 10.1111/hepr.12656
- Park B.H, Yoon J.M, Kim J.H, Moon J.H, Lee Y.H, Jang S.M, Kim Y.J. Pathologic Impact of Insulin Resistance and Sensitivity on the Severity of Liver Histopathology in Pediatric Non-Alcoholic Steatohepatitis. Yonsei Med J. 2017;58(4):756-762. doi: 10.3349/ymj.2017.58.4.756
- Cruz M.A, Cruz J.F, Macena L.B, de Santana D.S, Oliveira C.C, Lima S.O, Franca A.V. Association of the Nonalcoholic Hepatic Steatosis and Its Degrees With the Values of Liver Enzymes and Homeostasis Model Assessment-Insulin Resistance Index. Gastroenterol Res. 2015 Oct;8(5):260-264. doi: 10.14740/gr685w
- Arata M, Nakajima J, Nishimata S, Nagata T, Kawashima H. Nonalcoholic steatohepatitis and insulin resistance in children. World J Diabetes. 2014;5(6):917-23. doi: 10.4239/wjd.v5.i6.917
- Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, Suman A, Weber M, Cusi K. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015;61(1):153-60. doi: 10.1002/hep.27395
- Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Yamazaki M, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Sawai M, Yoshida M, Morioka C, Tsujimoto T, Kawaratani H, Fukui H. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non - alcoholic steatohepatitis. World J Gastroenterol. 2009;15(41):5193-5199. doi: 10.3748/wjg.15.5193
- Polyzos S.A, Kountouras J, Papatheodorou A, Katsiki E, Patsiaoura K, Zafeiriadou E, Papadopoulou E, Zavos C, Terpos E. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Ann Hepatol. 2013;12(5):749-757.
- Angulo P, Hui J.M, Marchesini G, Bugianesi E, George J, Farrell G.C, Enders F, Saksena S, Burt A.D, Bida J.P, Lindor K, Sanderson S.O, Lenzi M, Adams L.A, Kench J, Therneay T.M, Day C.P. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-854. doi: 10.1002/ hep.21496
- Wannamethee S.G, Shaper A.G, Lennon L, Whincup P.H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005 Dec;28(12):2913-2918. doi: 10.2337/diacare.28.12.2913
- Sattar N, Scherbakova O, Ford I, O’Reilly D.S, Stanley A, Forrest E, Macfarlane P.W, Packard C.J, Cobbe S.M, Shepherd J. The West of Scotland Coronary Prevention Study: Elevated alanine aminotransferase predicts new - onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes. 2004;53(11):2855-60. doi: 10.2337/diabetes.53.11.2855
- Del Ben M, Polimeni L, Baratta F, Bartimoccia S, Carnevale R, Loffredo L, Pignatelli P, Violi F, Angelico F. Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver. Int J Hepatol. 2014;2014:784985. doi: 10.1155/ 2014/784985
- Hossain I.A, Rahman Shah M.M, Rahman M.K, Ali L. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: Association of GGT and HOMA-IR with NAFLD. Diabetes Metab Syndr. 2016;10(1 Suppl 1):S25-S29. doi: 10.1016/j.dsx.2015.09.005
- Mankowska-Cyl A, Krintus M, Rajewski P, Sypniewska G. Gamma - glutamyltransferase activity as a surrogate biomarker of metabolic health status in young nondiabetic obese women. Biomark Med. 2017;11(5):449-457. doi: 10.2217/bmm-2016-0332
- Kunutsor S.K, Apekey T.A, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose - response meta - analysis. Int J Clin Pract. 2015;69(1):136-344. doi: 10.1111/ ijcp.12507
- Schreuder T.C, Marsman H.A, Lenicek M, van Werven J.R, Nederveen A.J, Jansen P.L, Schaap F.G. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010;298(3):G440-G445. doi: 10.1152/ajpgi.00322.2009
- Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):203. doi: 10.1186/s12944-017-0572-9
- Bril F, Sninsky J.J, Baca A.M, Superko H.R, Portillo Sanchez P, Biernacki D, Maximos M, Lomonaco R, Orsak B, Suman A, Weber M.H, Mc Phaul M.J, Cusi K. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. J Clin Endocrinol Metab. 2016;101(2):644-52. doi: 10.1210/jc.2015-3111
- Siddiqui M.S, Fuchs M, Idowu M.O, Luketic V.A, Boyett S, Sargeant C, Stravitz R.T, Puri P, Matherly S, Sterling R.K, Contos M, Sanyal A.J. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13(5):1000-1008.e3. doi: 10.1016/j.cgh.2014.10.008
- Younossi Z.M, Loomba R, Anstee Q.M, Rinella M.E, Bugianesi E, Marchesini G, Neuschwander-Tetri B.A, Serfaty L, Negro F, Caldwell S.H, Ratziu V, Corey K.E, Friedman S.L, Abdelmalek M.F, Harrison S.A, Sanyal A.J, Lavine J.E, Mathurin P, Charlton M.R, Goodman Z.D, Chalasani N.P, Kowdley K.V, George J, Lindor K. Diagnostic Modalities for Non - alcoholic Fatty Liver Disease (NAFLD), Non - alcoholic Steatohepatitis (NASH) and Associated Fibrosis. Hepatology. 2017 Dec 9 [Epub ahead of print].
- Gentili A, Daviddi G, De Vuono S, Ricci M.A, Di Filippo F, Alaeddin A, Mannarino M.R, Boni M, Vaudo G, Lupattelli G. Non - alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. Dig Liver Dis. 2016 Aug;48(8):904-908. doi: 10.1016/j.dld.2016.04.004